{"preliminary_commentary":{"by_channel":{"x_thread":5,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"ACCRU-GI-2017","nct_id":"NCT05199285","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=accru-gi-2017-nct05199285. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.","label":"Treatment (nivolumab, ipilimumab)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2026-02-01","type":"ACTUAL"},"conditions":["BCLC Stage B Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma","Locally Advanced Hepatocellular Carcinoma","Metastatic Hepatocellular Carcinoma","Stage III Hepatocellular Carcinoma AJCC v8","Stage IIIA Hepatocellular Carcinoma AJCC v8","Stage IIIB Hepatocellular Carcinoma AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8","Stage IVA Hepatocellular Carcinoma AJCC v8","Stage IVB Hepatocellular Carcinoma AJCC v8","Unresectable Hepatocellular Carcinoma"],"enrollment":{"count":15,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Ipilimumab","otherNames":["Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody","BMS-734016","Ipilimumab Biosimilar CS1002","MDX-010","MDX-CTLA4","Yervoy"],"type":"BIOLOGICAL"},{"name":"Nivolumab","otherNames":["BMS-936558","CMAB819","MDX-1106","NIVO","Nivolumab Biosimilar CMAB819","ONO-4538","Opdivo"],"type":"BIOLOGICAL"}],"last_update":"2026-08-04","lead_sponsor":"Academic and Community Cancer Research United","official_title":"A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2026-02-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Confirmed objective response rate (ORR)","timeFrame":"Up to 6 months"}],"references":[],"start_date":{"date":"2023-01-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab","url":"https://clinicaltrials.gov/study/NCT05199285"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/accru-gi-2017-nct05199285"}